Black Hawk Acquisition Shareholders Approve Its Proposed Business Combination With Vesicor Therapeutics

On October 13, 2026, shareholders of Black Hawk Acquisition Corporation approved the Business Combination Agreement with Vesicor Therapeutics, with approximately 77.3% of the outstanding ordinary shares represented at the meeting. The agreement, originally dated April 26, 2025, involves a merger between the two companies. The approval was part of a vote on eight proposals presented during the Extraordinary General Meeting.